Literature DB >> 22387339

Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions.

John L Butenhoff1, Elsbeth Pieterman, David J Ehresman, Gregory S Gorman, Geary W Olsen, Shu-Ching Chang, Hans M G Princen.   

Abstract

Some cross-sectional epidemiological studies have reported positive associations of serum concentrations of non-high density lipoprotein cholesterol with serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA). However, the strength of the reported associations is inconsistent for exposure-response across three orders of magnitude of serum PFOS and/or PFOA concentrations. These positive associations are unexpected based on toxicological/mechanistic studies, suggesting that the associations may have a biological, rather than a causal, basis. This study tested the hypothesis that PFOS and PFOA distribute into serum lipoprotein fractions such that increases in serum lipoproteins would result in corresponding increases in serum concentrations of PFOS and PFOA. Based on observed binding of PFOS and PFOA to isolated β-lipoproteins in physiological saline (96% and 40% bound, respectively) in preliminary experiments using ultrafiltration and LC-MS/MS methods, binding to human donor plasma lipoprotein fractions was investigated by two density gradient methods. The majority of PFOS and PFOA recovered masses were found in lipoprotein-depleted plasma. Plasma density gradient fractionation data suggested that maximally 9% of PFOS distributes to lipoprotein-containing fractions, yet only 1% or less of PFOA is so distributed. These data do not support a strong role for plasma lipoprotein fractions in explaining the inconsistent dose-response associations reported in cross-sectional epidemiological studies.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387339     DOI: 10.1016/j.toxlet.2012.02.013

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  11 in total

1.  Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014.

Authors:  Franco Scinicariello; Melanie C Buser; Lina Balluz; Kimberly Gehle; H Edward Murray; Henry G Abadin; Roberta Attanasio
Journal:  Chemosphere       Date:  2020-06-20       Impact factor: 7.086

2.  Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats.

Authors:  Wen Zhao; Jeremiah D Zitzow; David J Ehresman; Shu-Ching Chang; John L Butenhoff; Jameson Forster; Bruno Hagenbuch
Journal:  Toxicol Sci       Date:  2015-05-21       Impact factor: 4.849

3.  Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults-longitudinal analysis of the diabetes prevention program outcomes study.

Authors:  Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Abby F Fleisch; Antonia M Calafat; Thomas F Webster; Edward S Horton; Emily Oken
Journal:  Environ Int       Date:  2019-05-28       Impact factor: 9.621

4.  Bioavailability of inhaled or ingested PFOA adsorbed to house dust.

Authors:  Åsa Gustafsson; Bei Wang; Per Gerde; Åke Bergman; Leo W Y Yeung
Journal:  Environ Sci Pollut Res Int       Date:  2022-06-14       Impact factor: 5.190

5.  Associations between serum perfluoroalkyl acids and LINE-1 DNA methylation.

Authors:  Deborah J Watkins; Gregory A Wellenius; Rondi A Butler; Scott M Bartell; Tony Fletcher; Karl T Kelsey
Journal:  Environ Int       Date:  2013-11-18       Impact factor: 9.621

6.  Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study.

Authors:  Anne P Starling; Stephanie M Engel; Kristina W Whitworth; David B Richardson; Alison M Stuebe; Julie L Daniels; Line Småstuen Haug; Merete Eggesbø; Georg Becher; Azemira Sabaredzovic; Cathrine Thomsen; Ralph E Wilson; Gregory S Travlos; Jane A Hoppin; Donna D Baird; Matthew P Longnecker
Journal:  Environ Int       Date:  2013-11-02       Impact factor: 9.621

7.  Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA).

Authors:  Matteo Convertino; Timothy R Church; Geary W Olsen; Yang Liu; Eddie Doyle; Clifford R Elcombe; Anna L Barnett; Leslie M Samuel; Iain R MacPherson; Thomas R J Evans
Journal:  Toxicol Sci       Date:  2018-05-01       Impact factor: 4.849

8.  Increased Cardiovascular Risk Associated with Chemical Sensitivity to Perfluoro-Octanoic Acid: Role of Impaired Platelet Aggregation.

Authors:  Luca De Toni; Claudia Maria Radu; Iva Sabovic; Andrea Di Nisio; Stefano Dall'Acqua; Diego Guidolin; Salvatore Spampinato; Elena Campello; Paolo Simioni; Carlo Foresta
Journal:  Int J Mol Sci       Date:  2020-01-08       Impact factor: 5.923

9.  Binding of Per- and Polyfluoro-alkyl Substances to Peroxisome Proliferator-Activated Receptor Gamma.

Authors:  Nuno M S Almeida; Yiğitcan Eken; Angela K Wilson
Journal:  ACS Omega       Date:  2021-06-04

10.  Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice.

Authors:  Sandra L Rebholz; Thomas Jones; Robert L Herrick; Changchun Xie; Antonia M Calafat; Susan M Pinney; Laura A Woollett
Journal:  Toxicol Rep       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.